Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | METAP2 | P50579 | 1/20 | 0.48 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11594420 | 1.00 | NPC1 (0.60) | NPC1RAB9AALDH1A1KDM4EHPGD | |
| SCHEMBL262368 | 0.80 | NPC1 (0.58) | NPC1RAB9AALDH1A1KDM4EHPGD | |
| SCHEMBL6808280 | 0.80 | NPC1 (0.40) | NPC1RAB9AALDH1A1KDM4EHPGD | |
| SCHEMBL3468799 | 0.80 | NPC1 (0.58) | NPC1RAB9AALDH1A1KDM4EHPGD | |
| SCHEMBL29629450 | 0.80 | NPC1 (0.58) | NPC1RAB9AALDH1A1KDM4EHPGD | |
| SCHEMBL1157075 | 0.79 | ALDH1A1 (0.40) | NPC1RAB9AALDH1A1KDM4EHPGD | |
| SCHEMBL8385 | 0.79 | ALDH1A1 (0.59) | NPC1RAB9AALDH1A1KDM4EHPGD | |
| SCHEMBL28002036 | 0.78 | NPC1 (0.56) | NPC1RAB9AALDH1A1KDM4EHPGD | |
| Bromide SCHEMBL28425575 | 0.78 | NPC1 (0.56) | NPC1RAB9AALDH1A1KDM4EHPGD | |
| SCHEMBL104615 | 0.77 | ALDH1A1 (0.39) | NPC1RAB9AALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446222-B2 | Phenyl compounds | GLAXO GROUP LIMITED (GB) | 2008-11-04 | — | — | US | claimed |
| CN-101268060-A | Thiazolinone and oxazolinone compounds and application thereof as PTP1B inhibitor | TORRENT PHARMACEUTICALS LTD (IN) | 2008-09-17 | — | — | CN | claimed |
| WO-2007137190-A2 | FUNCTIONALLY DIVERSE MACROMOLECULES AND THEIR SYNTHESIS | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2007-11-29 | — | — | WO | claimed |
| US-20070225340-A1 | Phenyl Compounds And Their Use In The Treatment Of Conditions Mediated By The Action Of Pge2 At The Ep1 Receptor | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | US | claimed |
| US-20070098676-A1 | FUNCTIONALLY DIVERSE MACROMOLECULES AND THEIR SYNTHESIS | THE TEXAS A&M UNIVERSITY SYSTEM | 2007-05-03 | — | — | US | claimed |
| US-20070041933-A1 | Functionally Diverse Macromolecules and Their Synthesis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-22 | — | — | US | claimed |
| EP-1742916-A1 | PHENYL COMPOUNDS AND THEIR USE IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-01-17 | — | — | EP | claimed |
| WO-2005108369-A1 | PHENYL COMPOUNDS AND THEIR USE IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2005-11-17 | — | — | WO | claimed |
| EP-1119354-A4 | PERIPHERALLY ACTING ANTI-PRURITIC OPIATES | ADOLOR CORP (US) | 2003-02-12 | — | — | EP | claimed |
| JP-2002527392-A | — | — | 2002-08-27 | — | — | JP | claimed |
| EP-1119354-A1 | PERIPHERALLY ACTING ANTI-PRURITIC OPIATES | Adolor Corporation (US) | 2001-08-01 | — | — | EP | claimed |
| WO-2000021530-A1 | PERIPHERALLY ACTING ANTI-PRURITIC OPIATES | ADOLOR CORPORATION (US) | 2000-04-20 | — | — | WO | claimed |
| US-8551956-B2 | Compositions containing peptides with non-natural amino acids and methods of use | AVON PRODUCTS, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| CN-101084196-B | Process for producing N-halogenated organic compound | ALBEMARLE CORP | 2012-07-18 | — | — | CN | disclosed |
| US-20110319592-A1 | Process for the Purification of Antibodies Using Affinity Resins Comprising Specific Ligands | NOVO NORDISK A/S (DK) | 2011-12-29 | — | — | US | disclosed |
| EP-2346892-A1 | PROCESS FOR THE PURIFICATION OF ANTIBODIES USING AFFINITY RESINS COMPRISING SPECIFIC LIGANDS | Novo Nordisk A/S (DK) | 2011-07-27 | — | — | EP | disclosed |
| EP-0718298-A1 | Electron transporting tryptoanthrinime derivatives | MITA INDUSTRIAL CO. LTD. (JP) | 1996-06-26 | — | — | EP | disclosed |
| US-5521044-A | SENSITIVITY, DURABILITY | MITA INDUSTRIAL CO., LTD. (JP) | 1996-05-28 | — | — | US | disclosed |
| EP-0552740-A1 | Electrophotosensitive material | MITA INDUSTRIAL CO. LTD. (JP) | 1993-07-28 | — | — | EP | disclosed |
| EP-0329606-A2 | Antibiotics from myxocuccos | CIBA-GEIGY AG (CH) | 1989-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225340-A1 | Phenyl Compounds And Their Use In The Treatment Of Conditions Mediated By The Action Of Pge2 At The Ep1 Receptor | PTGER1, PTGER2, PTGDR | NPC1 810/4885RAB9A 1313/4885ALDH1A1 682/4885 |
| US-20110319592-A1 | Process for the Purification of Antibodies Using Affinity Resins Comprising Specific Ligands | FCGR1A, FCGR2A, FCGR3B | NPC1 4661/4885RAB9A 2548/4885ALDH1A1 3858/4885 |
| US-20070041933-A1 | Functionally Diverse Macromolecules and Their Synthesis | ECPAS, PCNA, MRPS22 | NPC1 4834/4885RAB9A 4652/4885ALDH1A1 2099/4885 |
| US-20070098676-A1 | FUNCTIONALLY DIVERSE MACROMOLECULES AND THEIR SYNTHESIS | ECPAS, PCNA, MRPS22 | NPC1 4834/4885RAB9A 4652/4885ALDH1A1 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.